These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 10578453)

  • 1. Neurotransmitter interactions in schizophrenia--therapeutic implications.
    Carlsson A; Waters N; Carlsson ML
    Biol Psychiatry; 1999 Nov; 46(10):1388-95. PubMed ID: 10578453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurotransmitter interactions in schizophrenia-therapeutic implications.
    Carlsson A; Waters N; Carlsson ML
    Eur Arch Psychiatry Clin Neurosci; 1999; 249 Suppl 4():37-43. PubMed ID: 10654107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of different monoamine receptors controlling MK-801-induced release of serotonin and glutamate in the medial prefrontal cortex: relevance for antipsychotic action.
    López-Gil X; Artigas F; Adell A
    Int J Neuropsychopharmacol; 2009 May; 12(4):487-99. PubMed ID: 18752722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rodent data and general hypothesis: antipsychotic action exerted through 5-Ht2A receptor antagonism is dependent on increased serotonergic tone.
    Martin P; Waters N; Schmidt CJ; Carlsson A; Carlsson ML
    J Neural Transm (Vienna); 1998; 105(4-5):365-96. PubMed ID: 9720968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unraveling monoamine receptors involved in the action of typical and atypical antipsychotics on glutamatergic and serotonergic transmission in prefrontal cortex.
    López-Gil X; Artigas F; Adell A
    Curr Pharm Des; 2010; 16(5):502-15. PubMed ID: 19909228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New perspectives on biological treatment of schizophrenia.
    Lingjaerde O
    Acta Psychiatr Scand Suppl; 1994; 384():102-7. PubMed ID: 7879631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
    Javitt DC
    Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurotransmitter aberrations in schizophrenia: new perspectives and therapeutic implications.
    Carlsson A; Hansson LO; Waters N; Carlsson ML
    Life Sci; 1997; 61(2):75-94. PubMed ID: 9217267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Neurobiological and pharmacologic aspects of atypical antipsychotic drugs].
    Sümegi A
    Orv Hetil; 2009 Aug; 150(33):1539-44. PubMed ID: 19643718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of the simultaneous enhancement of NMDA and dopamine D1 receptor-mediated neurotransmission in the effects of clozapine on phencyclidine-induced acute increases in glutamate levels in the rat medial prefrontal cortex.
    Abekawa T; Ito K; Koyama T
    Naunyn Schmiedebergs Arch Pharmacol; 2006 Dec; 374(3):177-93. PubMed ID: 17103144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of spontaneous tail-flicks in rats by blockade of transmission at N-methyl-D-aspartate receptors: roles of multiple monoaminergic receptors in relation to the actions of antipsychotic agents.
    Millan MJ; Gobert A; Bervoets K; Rivet JM; Veiga S; Brocco M
    J Pharmacol Exp Ther; 2000 Feb; 292(2):672-83. PubMed ID: 10640305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can 5-HT3 antagonists contribute toward the treatment of schizophrenia?
    Ellenbroek BA; Prinssen EP
    Behav Pharmacol; 2015 Feb; 26(1-2):33-44. PubMed ID: 25356732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The novel object recognition test in rodents in relation to cognitive impairment in schizophrenia.
    Rajagopal L; Massey BW; Huang M; Oyamada Y; Meltzer HY
    Curr Pharm Des; 2014; 20(31):5104-14. PubMed ID: 24345269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection.
    Lieberman JA; Bymaster FP; Meltzer HY; Deutch AY; Duncan GE; Marx CE; Aprille JR; Dwyer DS; Li XM; Mahadik SP; Duman RS; Porter JH; Modica-Napolitano JS; Newton SS; Csernansky JG
    Pharmacol Rev; 2008 Sep; 60(3):358-403. PubMed ID: 18922967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decoding schizophrenia.
    Javitt DC; Coyle JT
    Sci Am; 2004 Jan; 290(1):48-55. PubMed ID: 14682038
    [No Abstract]   [Full Text] [Related]  

  • 16. The role of 5-HT2A receptors in antipsychotic activity.
    Schmidt CJ; Sorensen SM; Kehne JH; Carr AA; Palfreyman MG
    Life Sci; 1995; 56(25):2209-22. PubMed ID: 7791509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence.
    Carlsson A; Waters N; Holm-Waters S; Tedroff J; Nilsson M; Carlsson ML
    Annu Rev Pharmacol Toxicol; 2001; 41():237-60. PubMed ID: 11264457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems.
    Meltzer HY; Huang M
    Prog Brain Res; 2008; 172():177-97. PubMed ID: 18772033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clozapine and haloperidol differently suppress the MK-801-increased glutamatergic and serotonergic transmission in the medial prefrontal cortex of the rat.
    López-Gil X; Babot Z; Amargós-Bosch M; Suñol C; Artigas F; Adell A
    Neuropsychopharmacology; 2007 Oct; 32(10):2087-97. PubMed ID: 17356574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beyond the dopamine receptor: novel therapeutic targets for treating schizophrenia.
    Coyle JT; Balu D; Benneyworth M; Basu A; Roseman A
    Dialogues Clin Neurosci; 2010; 12(3):359-82. PubMed ID: 20954431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.